Publications by authors named "R M Murata"

Tapinarof is a nonsteroidal, topical, aryl hydrocarbon receptor agonist approved for the treatment of atopic dermatitis (AD) in Japanese patients aged ≥12 years. We evaluated the efficacy and safety of tapinarof in Japanese pediatric patients aged 2 to 11 years with AD in a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial. Eligible patients (N = 121) were randomized 1:1:1 to receive tapinarof cream 0.

View Article and Find Full Text PDF

In order to characterize a novel restorative material, knowledge about the toxicological effect on human cells and the physical behavior of a glass ionomer cement (GIC) containing flavonoids was established. The flavonoids apigenin, naringenin, quercetin, and liquiritigenin were manually incorporated into a GIC. In the control group, no incorporation was performed.

View Article and Find Full Text PDF

Objective: To evaluate the ability of resveratrol to reduce dental caries in vitro and in vivo.

Methods: In part 1, a microcosm biofilm protocol was employed. One hundred twenty-six bovine enamel specimens were treated with: Resveratrol (50, 100, 200, 400 µg/mL), Phosphate buffered saline (negative control), Dimethyl sulfoxide (negative control) and 0.

View Article and Find Full Text PDF
Article Synopsis
  • Periodontitis (PD) can cause systemic changes that affect physical health and behavior, leading to increased oxidative stress and cognitive issues in a study involving male Wistar rats.
  • The study involved 24 rats divided into PD and control groups, with PD induced for 14 days, during which behavioral tests evaluated anxiety and cognitive function.
  • Results showed PD led to bone loss, changes in mineral content, increased anxiety, and cognitive decline, all linked to oxidative stress imbalances in their bodies.
View Article and Find Full Text PDF

Aims: Evidence for risk stratification using exercise stress echocardiography (ESE) in patients undergoing transcatheter aortic valve implantation (TAVI) for severe aortic stenosis (AS) is currently lacking. Cardiac power output (CPO) has demonstrated prognostic value in patients undergoing TAVI for severe AS. This study investigated prognoses in patients undergoing TAVI for severe AS and to explore the additional information that ESE can provide for risk stratification.

View Article and Find Full Text PDF